Rapid achievement of therapeutic anticoagulation positively affects outcome in patients undergoing cardioversion for persistent atrial fibrillation

被引:3
作者
Cutro, R [1 ]
Burkart, TA [1 ]
Curtis, AB [1 ]
机构
[1] Univ Florida, Coll Med, Div Cardiovasc Med, Clin Electrophysiol Sect, Gainesville, FL 32610 USA
关键词
atrial fibrillation; anticoagulation; electrical cardioversion; warfarin;
D O I
10.1002/clc.4960290209
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Current guidelines recommend anticoagulation with warfarin with documentation of an International Normalized Ratio (M) of 2-3 for 3 weeks prior to cardioversion of persistent atrial fibrillation (AF). Achievement of adequate anticoagulation often takes longer than 3 weeks, increasing the time to cardioversion. Hypothesis: The goal of the study was to quantify the total time elapsed for adequate anticoagulation and to identify differences in time to cardioversion between patients managed by primary care physicians (PCP) compared with those enrolled in a structured anticoagulation clinic (AC). Finally, we assessed the effect on treatment outcome between groups. Methods: A retrospective chart review identified those patients undergoing elective cardioversion who were started on warfarin at our medical center since 1997. The venue of anticoagulation management, time for adequate maintenance of M, and total time to cardioversion were recorded. A comparison was made between the two groups to identify the effect on treatment outcome. Multivariate analysis was performed to evaluate any effect comorbidities may have played on maintenance of normal sinus rhythm (NSR) within the treatment groups. Results: Of 83 patients, 48 had warfarin therapy monitored at their PCP and 35 were managed at our AC. Average time to therapeutic INR at AC and PCP was 29.1 +/- 9.3 and 50.7 +/- 6.8 days, respectively (p = 0.026). Average time to cardioversion at AC and PCP was 60.6 +/- 11.2 and 88.7 +/- 18.5 days (p = 0.041). At 12 months post cardioversion, 30 of 83 patients maintained NSR. Nineteen of 35 patients (54.3%) managed at AC maintained NSR compared with 11 of 48 patients (22.9%) managed at PCP (RR 0.61, 95% confidence interval 0.45-0.84) (p = 0.015). Conclusion: Therapeutic anticoagulation is more quickly achieved in a specialty anticoagulation clinic than at a PCP and positively affects therapy outcome.
引用
收藏
页码:78 / 82
页数:5
相关论文
共 14 条
[1]   Transesophageal echocardiography to guide electrical cardioversion in atrial fibrillation [J].
Asher, CR ;
Klein, AL .
CLEVELAND CLINIC JOURNAL OF MEDICINE, 2002, 69 (09) :713-718
[2]   RELATIONS BETWEEN LEFT ATRIAL APPENDAGE BLOOD-FLOW VELOCITY, SPONTANEOUS ECHOCARDIOGRAPHIC CONTRAST AND THROMBOEMBOLIC RISK IN-VIVO [J].
FATKIN, D ;
KELLY, RP ;
FENELEY, MP .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1994, 23 (04) :961-969
[3]   PREVALENCE, AGE DISTRIBUTION, AND GENDER OF PATIENTS WITH ATRIAL-FIBRILLATION - ANALYSIS AND IMPLICATIONS [J].
FEINBERG, WM ;
BLACKSHEAR, JL ;
LAUPACIS, A ;
KRONMAL, R ;
HART, RG .
ARCHIVES OF INTERNAL MEDICINE, 1995, 155 (05) :469-473
[4]   ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation:: Executive summary -: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation) [J].
Fuster, V ;
Rydén, LE ;
Asinger, RW ;
Cannom, DS ;
Crijns, HJ ;
Frye, RL ;
Halperin, JL ;
Kay, GN ;
Klein, WW ;
Lévy, S ;
McNamara, RL ;
Prystowsky, EN ;
Wann, LS ;
Wyse, DG ;
Gibbons, RJ ;
Antman, EM ;
Alpert, JS ;
Faxon, DP ;
Fuster, V ;
Gregoratos, G ;
Hiratzka, LF ;
Jacobs, AK ;
Russell, RO ;
Smith, SC ;
Klein, WW ;
Alonso-Garcia, A ;
Blomström-Lundqvist, C ;
De Backer, G ;
Flather, M ;
Hradec, J ;
Oto, A ;
Parkhomenko, A ;
Silber, S ;
Torbicki, A .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 38 (04) :1231-1265
[5]   Electrical remodeling in atrial fibrillation - Time course and mechanisms [J].
Goette, A ;
Honeycutt, C ;
Langberg, JJ .
CIRCULATION, 1996, 94 (11) :2968-2974
[6]   ANTICOAGULATION IN ATRIAL-FIBRILLATION - DOES EFFICACY IN CLINICAL-TRIALS TRANSLATE INTO EFFECTIVENESS IN PRACTICE [J].
GOTTLIEB, LK ;
SALEMSCHATZ, S .
ARCHIVES OF INTERNAL MEDICINE, 1994, 154 (17) :1945-1953
[7]   Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis [J].
Hart, RG ;
Benavente, O ;
McBride, R ;
Pearce, LA .
ANNALS OF INTERNAL MEDICINE, 1999, 131 (07) :492-+
[8]   Time course and frequency of subtherapeutic anticoagulation for newly prescribed warfarin anticoagulation before elective cardioversion of atrial fibrillation or flutter [J].
Kim, MH ;
Krishnan, K ;
Jain, S ;
Decena, BF .
AMERICAN JOURNAL OF CARDIOLOGY, 2001, 88 (12) :1428-+
[9]  
LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449
[10]   TRANSESOPHAGEAL ECHOCARDIOGRAPHICALLY FACILITATED EARLY CARDIOVERSION FROM ATRIAL-FIBRILLATION USING SHORT-TERM ANTICOAGULATION - FINAL RESULTS OF A PROSPECTIVE 4.5-YEAR STUDY [J].
MANNING, WJ ;
SILVERMAN, DI ;
KEIGHLEY, CS ;
OETTGEN, P ;
DOUGLAS, PS .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1995, 25 (06) :1354-1361